Olaparib in Patients With HRD Malignant Mesothelioma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Homologous Recombination Deficiency
- Mesothelioma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04515836
- Collaborators
- AstraZeneca
- Investigators
- Principal Investigator: Hedy L Kindler, MD University of Chicago
Get Well Soon